Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposureJonathan Brett, Sallie‐Anne Pearson, Emily A. Karanges et al.|Australian & New Zealand Journal of Psychiatry|2017Cited by 74
Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort studyJonathan Brett, Sallie‐Anne Pearson, Atheer Nassir et al.|British Journal of Clinical Pharmacology|2017Cited by 41
Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of “paradoxical” antidepressant responses in young personsEmily A. Karanges, Iain S. McGregor, P.S. van Nieuwenhuijzen et al.|Frontiers in Pharmacology|2013Cited by 21
Benchmarking prescription drug access patterns in pharmaceutical claims: a method for identifying high and potentially harmful opioid use in Australia and Canada?Bianca Blanch, Sallie‐Anne Pearson, Emilie J. Gladstone et al.|Journal of Pharmaceutical Health Services Research|2017Cited by 2
Policies affecting the supply and access of opioid analgesicsKellia Chiu, Lisa Bero, Emily A. Karanges et al.|The JBI Database of Systematic Reviews and Implementation Reports|2019Cited by 0